In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ablative Solutions gets $77mm via Series D

Executive Summary

Cardiovascular device maker Ablative Solutions Inc. raised $77mm in its Series D financing led by first-time backer Gilde Healthcare, returning investor BioStar Ventures, and an undisclosed new strategic corporate investor. Other existing shareholders Michigan Accelerator Fund, Novus Biotechnology, and individuals also participated. The company will use the funding to finish clinical trials in preparation of US and European regulatory submissions for its minimally invasive Peregrine System, a renal denervation technology to help reduce blood pressure for people with uncontrolled hypertension who are taking antihypertensive medication.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies